Enrollment in the phase IIb COBALT-1 trial of gemcabene (CI-1027) was small, due to the orphan population of homozygous familial hypercholesterolemia (HoFH), but meaningful, according to Lee Golden, chief medical officer of Gemphire Therapeutics Inc., who cited comparisons with phase II proof-of-concept studies for approved HoFH drugs Repatha (evolocumab, Amgen Inc.), Juxtapid (lomitapide, Aegerion Pharmaceuticals Inc.) and Kynamro (mipomersen, Kastle Therapeutics LLC).